Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
SAN CARLOS, Calif., Feb. 14, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present a corporate overview at the upcoming RBC Capital Markets 2018 Global Healthcare Conference on Thursday, February 22, 2018 at 2:35 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
